Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Case Report

Case Study Case Rep. 2012; 2(2): 38-45


CPI-613, an investigational novel anti - cancer agent, provides long- term stable disease without significant adverse effects in a patient with stage IV relapsed hepatocellular carcinoma

Neil Senzer; Cynthia Bedell; Claudia Maturo; John Luddy; Robert Rodriguez; Robert Shorr; King Lee.

Abstract
The current case study describes the safety and prolonged therapeutic effect of an investigational drug (CPI-613) in a patient with advancing relapsed hepatocellular carcinoma. The patient is a 73-year-old Caucasian male diagnosed with advancing Stage IV metastatic hepatocellular carcinoma. He had been treated with, and relapsed from, intra-arterial intrahepatic chemotherapy infusion therapy, sorafenib (Nexavar®), and an investigational drug CUDC-101. At the time of study entry, his disease was progressing. The liver was ~16 cm in size, had multiple heterogeneous abnormal signal lesions throughout, and had near complete replacement of parenchyma with tumor. There was a discrete mass (~5.2 cm) in the inferior right hepatic lobe, and another (~8.3 x 4.2 cm) in the inferior tip of the right hepatic lobe. There was one lesion (~2.4 cm) in the inferior spleen, and two (~2 cm and ~4.5 cm) in the superior spleen. There was also a left mid-abdominal mesenteric mass (~6.9 x 6.7 cm). During the 10 months of treatment with CPI-613, he maintained his performance status and the disease was stable. CPI-613 related adverse events were transient and of mild-to-moderate severity, and included fatigue, nausea, weakness, elevation of troponin I, anemia and elevation of hepatic enzymes.
CPI-613 therapy provided long-term Stable Disease and with minor transient adverse events in a patient with advancing T2 Stage IV relapsed hepatocellular carcinoma. This is an uncommon case where chemotherapy with an investigational drug is providing long-term stabilization of advanced metastatic relapsed hepatocellular carcinoma without significant adverse events.

Key words: Metastatic relapsed hepatocellular carcinoma;CPI-613;cancer cell mitochondrial energy metabolism;prolonged Stable Disease



Share this Article


Advertisement
American Journal of Diagnostic Imaging

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons